PharMerica Corporation (NYSE: PMC), announced that at its
special meeting of stockholders held today, a majority of the
outstanding shares of PharMerica common stock voted to approve the
adoption of the previously disclosed definitive merger agreement
pursuant to which a newly formed company controlled by KKR, with
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority
investor, will acquire PharMerica. The closing of the transaction
remains subject to customary closing conditions.
More than 99% of the votes cast, representing approximately 79%
of the outstanding shares of PharMerica common stock as of
September 28, 2017, the record date for the special meeting, were
cast in favor of adopting the merger agreement.
About PharMerica
PharMerica Corporation is a leading provider of pharmacy
services. PharMerica serves the long-term care, hospital pharmacy
management services, specialty home infusion and oncology pharmacy
markets.
PharMerica operates 99 institutional pharmacies, 20 specialty
home infusion pharmacies and 5 specialty oncology pharmacies in 45
states. PharMerica’s customers are institutional healthcare
providers, such as skilled nursing facilities, assisted living
facilities, hospitals, individuals receiving in-home care and
patients with cancer.
About KKR
KKR is a leading global investment firm that manages multiple
alternative asset classes, including private equity, energy,
infrastructure, real estate, credit and, through its strategic
manager partnerships, hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined
investment approach, employing world-class people, and driving
growth and value creation with KKR portfolio companies. KKR invests
its own capital alongside its partners' capital and provides
financing solutions and investment opportunities through its
capital markets business. References to KKR’s investments may
include the activities of its sponsored funds. For additional
information about KKR & Co. L.P. (NYSE: KKR), please visit
KKR's website at www.kkr.com and on Twitter @KKR_Co.
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is the first global
pharmacy-led, health and wellbeing enterprise. The company’s
heritage of trusted health care services through pharmaceutical
wholesaling and community pharmacy care dates back more than 100
years.
Walgreens Boots Alliance is the largest retail pharmacy, health
and daily living destination across the U.S. and Europe. Walgreens
Boots Alliance and the companies in which it has equity method
investments together have a presence in more than 25* countries and
employ more than 385,000* people. The company is a global leader in
pharmacy-led, health and wellbeing retail and, together with the
companies in which it has equity method investments, has more than
13,200* stores in 11* countries as well as one of the largest
global pharmaceutical wholesale and distribution networks, with
more than 390* distribution centers delivering to more than
230,000** pharmacies, doctors, health centers and hospitals each
year in more than 20* countries. In addition, Walgreens Boots
Alliance is one of the world’s largest purchasers of prescription
drugs and many other health and wellbeing products.
The company’s portfolio of retail and business brands includes
Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as
increasingly global health and beauty product brands, such as No7,
Soap & Glory, Liz Earle, Sleek MakeUP and Botanics.
The company ranks No. 1 in the Food and Drug Stores industry of
Fortune magazine’s 2017 list of the World’s Most Admired
Companies.
More company information is available at
www.walgreensbootsalliance.com.
* As of 31 August 2017, using publicly available information for
AmerisourceBergen.
** For 12 months ending 31 August 2017, using publicly available
information for AmerisourceBergen.
CAUTION ABOUT FORWARD-LOOKING STATEMENTS
Certain statements in this communication regarding the proposed
acquisition of PharMerica, including any statements regarding the
expected timetable for completing the proposed transaction,
benefits of the proposed transaction, future opportunities, future
financial performance and any other statements regarding future
expectations, beliefs, plans, objectives, financial conditions,
assumptions or future events or performance that are not historical
facts are “forward-looking” statements made within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The words
“anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,”
“estimate,” “probable,” “project,” “forecasts,” “predict,”
“outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,”
“may,” “might,” “anticipate,” “likely” “plan,” “positioned,”
“strategy,” and similar expressions, and the negative thereof, are
intended to identify forward-looking statements. All
forward-looking information are subject to numerous risks and
uncertainties, many of which are beyond the control of PharMerica,
that could cause actual results to differ materially from the
results expressed or implied by the statements. These risks and
uncertainties include, but are not limited to: the timing to
consummate the proposed transaction; the risk that a condition to
closing of the proposed transaction may not be satisfied or that
the closing of the proposed transaction might otherwise not occur;
the diversion of management time on transaction-related issues; and
risk that the transaction and its announcement could have an
adverse effect on PharMerica’s ability to retain customers and
retain and hire key personnel. Additional information concerning
these and other risk factors can be found in PharMerica’s filings
with the SEC and available through the SEC’s Electronic Data
Gathering and Analysis Retrieval system at http://www.sec.gov,
including PharMerica’s most recent Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The
foregoing list of important factors is not exclusive. PharMerica’s
forward-looking statements are based on assumptions that PharMerica
believes to be reasonable but that may not prove to be accurate.
PharMerica assumes no obligation to update or revise any
forward-looking statements as a result of new information, future
events or otherwise, except as may be required by law. Readers are
cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109006331/en/
PharMerica CorporationRobert E. Dries, 502-627-7475Executive
Vice President andChief Financial Officer
Pharmerica Corp. (delisted) (NYSE:PMC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Pharmerica Corp. (delisted) (NYSE:PMC)
Historical Stock Chart
From Oct 2023 to Oct 2024